Nonprofit Pursues Oncology Drugs
Source: Life Science Leader
By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Reboot Rx does not aim to rescue undeveloped drugs; it intends to give approved generic drugs a new life in oncology. The company is founded on a well-supported assumption: Many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.
VIEW THE MAGAZINE ARTICLE! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader X
Subscribe to Life Science Leader